Literature DB >> 19710586

Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada.

Susan Hahné1, Jeannette Macey, Rob van Binnendijk, Robert Kohl, Sharon Dolman, Ytje van der Veen, Graham Tipples, Helma Ruijs, Tony Mazzulli, Aura Timen, Anton van Loon, Hester de Melker.   

Abstract

BACKGROUND: In The Netherlands and Canada the measles, mumps, rubella vaccine coverage is high. In 2004 a rubella outbreak started in the Netherlands in a population subgroup with low coverage, with subsequent spread to Canada.
METHODS: We examined data on rubella cases in the Netherlands and Canada reported between September 2004 and July 2005. In The Netherlands we established enhanced surveillance for congenital rubella while in Canada we carried out a cohort study to estimate vaccine effectiveness.
RESULTS: In The Netherlands and Canada, 387 and 309 rubella cases were reported, respectively. Of these, 97% were in unvaccinated individuals of orthodox protestant denomination. Reported consequences of rubella in pregnancy were 2 fetal deaths and 14 infants with congenital infection. Of the latter, 11 had clinical defects including deafness in all but eye defects in none. The estimated vaccine effectiveness was 99.3% (95% CI: 95.3%-99.9%). Closely related strains of rubella virus genotype 1G were found in Dutch and Canadian cases.
CONCLUSIONS: A large rubella outbreak occurred in The Netherlands with spread to Canada in a population subgroup with religious objections to vaccination. Its major public health importance was due to the high burden of congenital disease, international spread and implications for measles and rubella surveillance and elimination. Congenital deafness occurred more frequently and eye defects less frequently than expected. The estimated rubella vaccine effectiveness was very high. Our results demonstrate the risks associated with heterogeneity in rubella vaccine coverage. High rubella vaccine coverage in all population subgroups and sensitive surveillance are crucial for elimination of rubella and CRS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710586     DOI: 10.1097/INF.0b013e3181a3e2d5

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  29 in total

1.  Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus.

Authors:  Gaby P Smits; Pieter G van Gageldonk; Leo M Schouls; Fiona R M van der Klis; Guy A M Berbers
Journal:  Clin Vaccine Immunol       Date:  2012-01-11

Review 2.  The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases.

Authors:  Sarah E Wilson; Shelley L Deeks; Todd F Hatchette; Natasha S Crowcroft
Journal:  CMAJ       Date:  2011-11-14       Impact factor: 8.262

Review 3.  The rise (and fall?) of parental vaccine hesitancy.

Authors:  Charitha Gowda; Amanda F Dempsey
Journal:  Hum Vaccin Immunother       Date:  2013-06-06       Impact factor: 3.452

4.  Assessment of humoral and cell-mediated immune response to measles-mumps-rubella vaccine viruses among patients with asthma.

Authors:  Kwang Ha Yoo; Kanishtha Agarwal; Michael Butterfield; Robert M Jacobson; Gregory A Poland; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2010 Nov-Dec       Impact factor: 2.587

5.  The status of rubella IgG antibody titer between antenatal and postnatal among pregnant non-immune to rubella.

Authors:  Irfana Rasool; Ayesha Azad; Saeed Baradwan; Muhammad Salman Bashir; Dania Al-Jaroudi
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

6.  Rubella antibodies in Australian immunoglobulin products.

Authors:  Megan K Young; Joseph Bertolini; Pushpa Kotharu; Darryl Maher; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

7.  Further efforts in the achievement of congenital rubella syndrome/rubella elimination.

Authors:  Vanessa Cozza; Domenico Martinelli; Maria Giovanna Cappelli; Silvio Tafuri; Francesca Fortunato; Rosa Prato
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage.

Authors:  Sandra Waaijenborg; Susan J M Hahné; Liesbeth Mollema; Gaby P Smits; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker; Jacco Wallinga
Journal:  J Infect Dis       Date:  2013-05-08       Impact factor: 5.226

9.  How to determine protective immunity in the post-vaccine era.

Authors:  Carmen L Charlton; Florence Y Lai; Douglas C Dover
Journal:  Hum Vaccin Immunother       Date:  2016-04-02       Impact factor: 3.452

10.  Outbreak of measles in an unvaccinated population, British Columbia, 2014.

Authors:  M Naus; D Puddicombe; M Murti; C Fung; R Stam; S Loadman; M Krajden; P Tang; M Lem
Journal:  Can Commun Dis Rep       Date:  2015-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.